VERAXA Biotech AG (NASDAQ: VRXA) has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has completed the discovery phase and is moving into the next stage of development. The company also revealed that it has expanded its intellectual property portfolio with new patent filings related to its BiTAC platform and other antibody technologies, underscoring its commitment to building a diversified oncology pipeline.
The VXA-222 program, which leverages VERAXA's proprietary antibody engineering, linker, and conjugation technologies, is one of the company's more advanced development programs. Although it is not based on VERAXA's BiTAC platform, the bsADC candidate benefits from the successful collaboration with OmniAb Inc., which delivered a portfolio of therapeutic antibody binders. With the discovery phase complete, VERAXA will now focus on engineering the final bispecific ADC candidate and advancing preclinical validation.
This milestone follows the collaboration with OmniAb that began in May 2025 (https://nnw.fm/nIprz). The progress on VXA-222 is part of VERAXA's broader strategy to develop novel cancer therapies targeting difficult-to-treat cancers, including bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats.
In parallel, VERAXA has strengthened its intellectual property estate with its first BiTAC-related patent filings, as well as additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with new applications expected to extend protection into at least 2047.
The expansion of the patent portfolio is a critical step for VERAXA as it seeks to protect its innovative platforms and maintain a competitive edge in the rapidly evolving field of antibody-based cancer therapeutics. By securing intellectual property around its BiTAC platform and other technologies, the company aims to safeguard its future products and potential partnerships.
VERAXA's pipeline is designed to address significant unmet medical needs in oncology, with a focus on solid tumors and hematologic malignancies. The company's approach combines cutting-edge science with strategic collaborations to accelerate the development of next-generation therapies. The advancement of VXA-222 and the strengthening of its patent portfolio position VERAXA for continued growth and potential value creation for shareholders.
Investors and industry observers are closely watching VERAXA's progress, as the company emerges as a leader in the development of novel cancer treatments. The recent developments highlight VERAXA's ability to execute on its strategic objectives and advance its pipeline toward clinical trials.
For more information on VERAXA and its latest news, visit the company's newsroom at https://nnw.fm/VRXA.
